首页> 外文OA文献 >P2.01-102 Outcome of Patients with EGFR Exon 19 Mutation in a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy

【2h】

P2.01-102 Outcome of Patients with EGFR Exon 19 Mutation in a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy

机译：eGFR外显子19突变患者患者的结果，将吉替尼与化疗比较Gefitinib

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
K. Prabhash; V. Noronha; V. Patil; A. Joshi; A. Chougule; A. Mahajan; A. Janu; R. Kumar; S. More; S. Goud; N. Kumar; N. Daware; A. Bhattacherjee; S. Shah; A. Yadav; S. Banavali;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer - data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002) [J] . Miyauchi Eisaku, Inoue Akira, Kobayashi Kunihiko, Japanese journal of clinical oncology. . 2015,第7期

机译：吉非替尼一线治疗后EGFR突变阳性的晚期非小细胞肺癌的化疗效果-来自吉非替尼与卡铂加紫杉醇（NEJ002）比较的随机III期研究数据
2. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na?ve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002) [J] . Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第1期

机译：最新的总体生存结果来自一项随机的，比较吉非替尼与卡铂-紫杉醇治疗具有敏感性EGFR基因突变的非小细胞肺癌的三期临床试验（NEJ002）
3. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). [J] . Takeda K, Hida T, Sato Journal of Clinical Oncology . 2010,第5期

机译：在日本晚期晚期非小细胞肺癌患者中进行的铂双药化疗随后进行吉非替尼与持续铂双药化疗的III期随机试验：一项西日本胸腔肿瘤小组试验的结果（WJTOG0203）。
4. A Health Belief Messaging Framework and a Randomized Controlled Trial of an SMS-Based Intervention for Cancer Patient Outcomes [C] . Coursaris Constantinos K., Spoelstra Sandra L., Given Charles W., Annual Hawaii International Conference on System Sciences . 2015

机译：健康信念消息传递框架和基于SMS的癌症患者预后干预的随机对照试验。
5. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
6. Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations [O] . Satoshi Oizumi, Shunichi Sugawara, Koichi Minato, 2013

机译：NEJ005 / TCOG0902的更新生存结局：吉非替尼同时用药和序贯交替用吉非替尼联合化学疗法治疗先前未经治疗的具有敏感性EGFR突变的非小细胞肺癌的随机II期研究
7. P1.01-88 PS 2 Patients with Advanced EGFR Mutant NSCLC: Subset Analysis of a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy [O] . K. Prabhash, V. Noronha, V. Patil, 2019

机译：P1.01-88 PS 2晚期EGFR突变体NSCLC的患者：III期随机试验的子集分析将GEFITINIB与化疗进行吉维替尼

P2.01-102 Outcome of Patients with EGFR Exon 19 Mutation in a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy

著录项

引文网络

相似文献

相关主题

期刊订阅